The aforementioned studies emphasize an increasingly nuanced approach to treatment decision-making in AML as molecular data such as types of mutations (i.e., FLT3-ITD versus FLT3-TKD) and co-mutational patterns (i.e., IDH1/2 with DNMT3A or RTK pathway mutations) have important prognostic and treatment implications. The gene discussed is FLT3; the disease is acute myeloid leukemia.